Pharmacogenetics of warfarin - Is testing clinically indicated?

Australian Prescriber

Volumn 32, Issue 3, 2009, Pages 76-80

  Martin, Jennifer H ^a,b  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Anticoagulation; Cytochrome P450 system; Vitamin K

Indexed keywords

CYTOCHROME P450 2C9; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); VITAMIN K GROUP; WARFARIN;

AGE; COST EFFECTIVENESS ANALYSIS; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HYPOTHYROIDISM; MAINTENANCE DRUG DOSE; PHARMACOGENETICS; REVIEW; VITAMIN INTAKE;

EID: 66749091492     PISSN: 03128008     EISSN: None     Source Type: Journal    
DOI: 10.18773/austprescr.2009.038     Document Type: Review

References (16)

1. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-1457
2. Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996;156:409-416
3. Jones M, McEwan P, Morgan CL, Peters JR, Goodfellow J, Currie CJ. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart 2005;91:472-477
4. Flockhart DA. Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine. 2007. www.medicine.iupui.edu/clinpharm/ ddis/clinicalTable.asp [cited 2009 May 5]
5. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999;353:717-719
6. Wilke RA, Berg RL, Vidaillet HJ, Caldwell MD, Burmester JK, Hillman MA. Impact of age, CYP2C9 genotype and concomitant medication on the rate of rise for prothrombin time during the first 30 days of warfarin therapy. Clin Med Res 2005;3:207-213
7. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000;96:1816-1819
8. Caldwell MD, Berg RL, Zhang KQ, Glurich I, Schmelzer JR, Yale SH, et al. Evaluation of genetic factors for warfarin dose prediction. Clin Med Res 2007;5:8-16.
9. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005;352:2285-2293
10. Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005;106:135-140
11. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005;106:2329-2333
12. Sconce E, Avery P, Wynne H, Kamali F. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 2007;109:2419-2423
13. Roberts GW, Druskeit T, Jorgenson LE, Wing LM, Gallus AS, Miller C, et al. Comparison of an age adjusted warfarin loading protocol with empirical dosing and Fennerty's protocol. Aust N Z J Med 1999;29:731-736
14. Oates A, Jackson PR, Austin CA, Channer KS. A new regimen for starting warfarin therapy in out-patients. Br J Clin Pharmacol 1998;46:157-161
15. The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009;360:753-764
16. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ 1997;16:1-31.